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E-mail address: chunyanli5@yahoo.com.cn (C. Li).The SOD1-G93A transgenic mouse is a widely used ALS model, but the death of lower motor neurons
is the hallmark. Here, we show that the SOD1-G93A transgene and HO-1 are preferentially over-
expressed in the lumbar spinal cord, particularly in the activated astrocytes of the transgenic mice.
We also show down-regulation of GLT-1 in spite of the proliferating astrocytes. However, GLT-1,
SOD1-G93A transgene and HO-1 expression were not obviously changed in the motor cortex. Our
data link spinal cord vulnerability to relatively decreased expression of GLT-1, and high expression
of the transgene and HO-1 in astrocytes in SOD1-G93A transgenic mice.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction G93A transgenic mice [11,12]. In the present study, we comparedAmyotrophic lateral sclerosis (ALS) is a progressively debilitat-
ing disease, causing selective loss of motor neurons from spinal
cord, brainstem, and cortex, and results in paralysis and death.
Approximately 5–10% of ALS cases are familial, 20% of which are
caused by SOD1 mutations [1,2]. Transgenic mice expressing hu-
man SOD1-G93A replicate most phenotypes of human ALS, includ-
ing weakness of hind limbs, loss of motor neurons, decreased
glutamate uptake and formation of inclusions [2–4]. The pathogen-
esis of ALS likely involves multiple mechanisms, including excito-
toxicity, oxidative stress and protein aggregation [5–7]. The exact
mechanism of motor neuron degeneration remains undeﬁned.
Motor neuron destruction in SOD1-G93A mice occurs primarily
in the spinal cord, but the reason for spinal cord susceptibility is
poorly understood. Mice expressing human SOD1-G93A develop
astrocytosis in the spinal cord [8]. Signiﬁcant loss of GLT-1 was
previously reported in the spinal cord of SOD1-G85R transgenic
mice [9] and SOD1-G93A transgenic rats [10]. However, conﬂicting
data exist with respect to GLT-1 level in the spinal cord of SOD1-chemical Societies. Published by E
ogy, the Second Hospital of
hijiazhuang, Hebei Provincethe expression levels of both GFAP and GLT-1 in different central
nervous system (CNS) parts in both SOD1-G93A mice and their
non-transgenic littermates. Although, SOD1-G93A expression in
transgenic rats was reported to increase in the spinal cord during
the disease progression [10], the expression levels of SOD1-G93A
in different CNS parts of transgenic mice are not well understood.
Therefore, we have compared its expression levels in various CNS
tissues. Moreover, oxidative stress has been increasingly impli-
cated in the neurodegenerative process of ALS. Heme oxygenase-
1 (HO-1) is a stress-responsive protein, whose expression is readily
elevated in response to oxidative stress and injury. Using HO-1 as a
biomarker of oxidative stress, we also compared the stress state of
different CNS tissues in SOD1-G93A transgenic mice. At the same
time, the cellular localization of SOD1 and HO-1 were analyzed
using both immunohistochemistry and immunoﬂuorescence. Our
data provide important insight into the vulnerability of spinal cord
in SOD1-G93A transgenic mice.
2. Materials and methods
2.1. Animals
Transgenic hSOD1-G93A mice and their non-transgenic litter-
mates were generated by breeding male hemizygous carrierslsevier B.V. All rights reserved.
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which were purchased from the Jackson Laboratories (Bar Harbor,
ME, USA). PCR-based genotyping of tail/blood DNA was used to
identify the transgenic mice [2]. The animals were maintained in
a 12-h light/dark cycle with ad libitum access to water and diet.
To monitor disease progression, the animals were inspected
daily and weighed twice a week starting at 12 weeks of age. Dis-
ease onset was determined at the earliest presentation of gait
abnormalities. When the animal could not upright itself in 30 s
after being placed on either side or its back, it was scored as end
stage [13]. After anesthesia with chloral hydrate (20 mg/mice), ani-
mals were sacriﬁced at pre-symptomatic stage (60 days of age),
disease onset (100–120 days of age) or end stage (130–150 days
of age), and the spinal cord, brain stem, hippocampus, cerebellum,
and motor cortex were obtained for analysis. Experiments were
carried out according to the regulations of laboratory animal man-
agement promulgated by the Ministry of Science and Technology
of the People’s Republic of China, which are in accordance with
the guidelines published in the NIH Guide for the Care and Use
of Laboratory Animals.
2.2. Immunoblotting analysis
Whole tissue extracts were prepared using a total protein
extraction kit (Applygen Technologies Inc.) following the manufac-
turer’s instruction. Protein levels in the extracts were quantiﬁed
using the Bradford method. Forty micrograms of protein from each
sample was run on 10% SDS–PAGE gels and blotted onto PVDF
membranes. After probing the membranes with speciﬁc antibod-
ies, including anti-b-actin, anti-SOD1 (Santa Cruz, CA, USA), and
anti-HO-1 (StressGen Biotechnologies, Victoria, Canada), IRDye™
700DX anti-mouse IgG, IRDye™ 800DX anti-rabbit IgG and IR
Dye™ 800DX anti-goat IgG (Rockland, Maine, USA) were used
and the bands of interest were detected using an Odyssey Infrared
Imaging System (LI-COR, Lincoln, NE). Band intensity was quanti-
ﬁed using the Odyssey Infrared Imaging System Version 2.1.12
and was normalized by the b-actin band. The original green or
red color of a band was converted to black and white colors for
data presentation.
2.3. Immunohistochemistry
After transcardial perfusion with 4% paraformaldehyde and fur-
ther ﬁxation for 24 h in the same ﬁxative solution, lumbar enlarge-
ment was cut into 20 lm free-ﬂoating sections using a Leica VT
1000S vibratome. The sections were washed for three times in
phosphate-buffered saline (PBS) and then perforated with 0.3% Tri-
ton X-100. After blocking with 3% H2O2 in methanol for 15 min and
10% horse serum for 1 h at room temperature, the sections were
incubated overnight at 4 C with antibodies against SOD1 (Santa
Cruz, 1:200), and HO-1 (Stressgen Biotechnologies, 1:500), respec-
tively. The sections were subsequently incubated with a biotin-
conjugated secondary antibody (ZSGB-BIO, 1:200) for 2 h at room
temperature, followed by incubation with HRP-conjugated strepta-
vidin (ZSGB-BIO, 1:200) for 1 h at room temperature and treatment
with 0.03% diaminobenzidine as a chromogen for 10 min. Slides
were mounted and analyzed by light microscopy (Nikon 50i).
2.4. Confocal microscopy
The lumbar spinal cord ﬁxed in 4% paraformaldehyde was cryo-
protected in a 30% sucrose/4% paraformaldehyde solution for 12 h
and then sliced into 30 lm sections using a Leica CM1850 freezing
microtome. The sections were stained for HO-1 antibody in combi-
nation with anti-GFAP (Chemicon) or anti-SMI-32 (Sternberger)
antibodies for double-labeling. Anti-SOD1 antibody in combinationwith anti-GFAP antibody was used for double-labeling. Fluorescent
secondary antibodies (FITC conjugate of goat anti-rabbit, FITC con-
jugate of rabbit anti-goat and Cy5 conjugate of horse anti-mouse)
were used. Slides were mounted and analyzed by ﬂuorescent con-
focal microscopy (Olympus FV1000).
2.5. Reverse transcription-polymerase chain reaction (RT-PCR)
Human SOD1 mRNA levels from lumbar spinal cord and motor
cortex of SOD1-G93A transgenic mice were evaluated by semi-
quantitative RT-PCR, using GAPDH gene as internal standard. Total
RNA was extracted from lumbar spinal cord and motor cortex at
pre-symptomatic, onset and end stages of SOD1-G93A mice with
Trizol reagent (Invitrogen Life Technologies, CA). cDNA was syn-
thesized using M-MLV reverse transcriptase and random primers
(Promega, WI). PCR primers speciﬁc to each gene are listed as fol-
lows: hSOD1, 50-CAT CAG CCC TAA TCC ATC TGA-30 and 50-CGC GAC
TAA CAA TCA AAG TGA-30 (236-bp); GAPDH, 50-ATG ACA TCA AGA
AGG TGG TG-30 and 50-CAT ACC AGG AAA TGA GCT TG-30 (177-bp).
PCR was carried out in a 25 ll reaction volume and run for 35 cy-
cles, using GoTaq Green Master Mix from Promega. The ampliﬁca-
tion products were run in 2% agarose gel and stained with
GoldView™ (Solarbio, Beijing, China). Quantitative analysis of RT-
PCR results was performed by Gel-Pro Analyzer Version 3.0.
2.6. Statistical analysis
Results were expressed as means ± S.D. Statistical analyses were
performed using one-way ANOVA followed by Student’s t-test with
SAS 8.0 statistical software. Differences were considered signiﬁcant
at P < 0.05.3. Results
3.1. Differential expression of GFAP and GLT-1 in CNS tissues of non-
transgenic littermates and time course of GFAP and GLT-1 expression
in the lumbar spinal cord and cortex of SOD1-G93A transgenic mice
Since excitotoxicity is believed to play a signiﬁcant role in the
pathogenesis of motor neuron degeneration in ALS, and lumbar
spinal cord is the main affected region in SOD1-G93A transgenic
mice, we examined the expression of GFAP and GLT-1 in CNS tis-
sues of the non-transgenic littermates. GFAP expression levels in
the spinal cord and brain stem were similar but were signiﬁcantly
higher than that in the cerebellum, hippocampus and cortex. For
example, GFAP level in the lumbar spinal cord was approximately
twice as high as that in the cortex. In contrast, highest level of GLT-
1 was detected in the cortex, which was approximately twofold
higher than that in the spinal cord and brain stem (Fig. 1A). GLT-
1 level in the cortex was approximately twice of that in the lumbar
spinal cord. These results suggest that astrocytes in the spinal cord
and brain stem may express relatively lower levels of GLT-1 and
may be less capable of protecting against glutamate-mediated
excitotoxicity than those in the brain cortex.
The expression levels of GFAP and GLT-1 in the lumbar spinal
cord and motor cortex were measured at pre-symptomatic
(60 days of age), disease onset (100–120 days of age) and end
stages (130–150 days of age) of SOD1-G93A mice, as well as in
their non-transgenic littermates (110–130 days of age). GLT-1
expression levels before and at disease onset in the lumbar spinal
cord of the transgenic mice appeared to be somewhat higher than
that in their littermates at the same age, but decreased signiﬁ-
cantly at the end stage. GFAP levels in the spinal cord of transgenic
mice before disease onset was comparable to that in their litter-
mates, but increased signiﬁcantly at disease onset and increased
Fig. 1. Differential expression of GFAP and GLT-1 in CNS tissues of non-transgenic littermates and their changes with disease progression in lumbar spinal cord and motor
cortex of SOD1-G93A transgenic mice. Total protein extracts from different CNS tissues of non-transgenic littermates at 110–130 days of age and SOD1-G93A transgenic mice
at pre-symptomatic, onset and end stages were examined for levels of GFAP and GLT-1 by Western blot. b-Actin was used as a control. (A) GLT-1 is highly expressed in
hippocampus and cortex, while GFAP expression is relative rich in the spinal cord and brain stem. *P < 0.05 compared with the level in cervical spinal cord. (B) Time course of
GFAP and GLT-1 expression in the lumbar spinal cord of SOD1-G93A transgenic mice. *P < 0.05 compared with the level in the littermates. (C) Time course of GFAP and GLT-1
expression in the motor cortex of SOD1-G93A transgenic mice. No signiﬁcant difference was found when compared with the littermates. The results are representative of
triplicate experiments. C: cervical; T: thoracic; L: lumbar; Mo: Medulla oblongata; Po: pons; Mi: midbrain; Ce: cerebellum; Hi: hippocampus; Co: cortex. Pre-sympt:
representative of pre-symptomatic stage.
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GFAP expression in the cortex of the transgenic mice showed a
time-related change and was similar to that in their littermates
(Fig. 1C).
3.2. Differential expression of the SOD1-G93A transgene in CNS tissues
of the transgenic mice
Expression of the human SOD1-G93A is the cause of motor
neuron degeneration in SOD1-G93A transgenic mice. The SOD1mutant is presumably expressed in all types of cells and tissues
in the mice. However, its expression level differed signiﬁcantly
among spinal cord and other CNS tissues at as early as 60 days of
age in SOD1-G93A transgenic mice. Its expression was markedly
higher in the spinal cord than in other tissues (Fig. 2A). Its level
in the lumbar spinal cord was the highest, which was approxi-
mately sixfold higher than in the cortex at the end stage. Similarly,
wild type hSOD1 transgenic mice also had higher expression of hu-
man SOD1 in the lumbar spinal cord (about fourfold hither) than in
the cortex (Fig. 2B). Moreover, the SOD1-G93A protein in the
Fig. 2. Increased protein expression and decreased mRNA level of the SOD1-G93A transgene in the lumbar spinal cord at end stage of SOD1-G93A transgenic mice. Different
CNS tissues were harvested from non-transgenic littermates (110–130 days of age) and transgenic mice at pre-symptomatic stage, disease onset or end stage, respectively.
Crude tissue extracts were examined for SOD1 expression by Western blot, using b-actin as a control. (A) The expression of SOD1-G93A transgene in the spinal cord was
higher than any other CNS tissues at different disease stages. (B) Total SOD1 expression in lumbar spinal cord and motor cortex of hSOD1-G93A transgenic mice at end stage
and wild type hSOD1 transgenic mice at the same age. *P < 0.05 compared with motor cortex of the same transgenic mice. (C and D) Time course of SOD1-G93A transgene
expression in the lumbar spinal cord and motor cortex of the transgenic mice. (E and F) Histograms of SOD1 expression in C and D, respectively. *P < 0.05 compared with
mouse SOD1 expression in non-transgenic littermates. (G) Time course of human SOD1 mRNA levels in the lumbar spinal cord and motor cortex of SOD1-G93A transgenic
mice. (H) Histograms of SOD1 expression in G. *P < 0.05 compared with pre-symptomatic L; D, compared with end L. The results are representative of triplicate experiments.
Pre-sympt, representative of pre-symptomatic stage. C: cervical; T: thoracic; L: lumbar; Co: motor cortex; Hi: hippocampus; Ce: cerebellum. hSOD1: human SOD1; mSOD1:
mouse SOD1.
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gressed (Fig. 2C and E). However, the expression of SOD1 mutant in
the motor cortex of SOD1-G93A transgenic mice did not change
signiﬁcantly at different disease stages (Fig. 2D and F). In order
to further explore the reason why lumbar spinal cord had moreSOD1 mutant proteins, we performed RT-PCR analysis on human
SOD1 in lumbar spinal cord and motor cortex of SOD1-G93A trans-
genic mice at different stages. Interestingly, the human SOD1
mRNA level showed constantly higher (about 1.5 fold higher than
lumbar spinal cord) in the motor cortex, while it increased at dis-
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bar spinal cord of SOD1-G93A transgenic mice (Fig. 2G and H).
3.3. Proliferated astrocytes expressed SOD1 in the lumbar spinal cord
of symptomatic SOD1-G93A transgenic mice
We also observed that as the disease progressed, GFAP-positive
astrocytes increased and motor neurons decreased progressively
(data not shown). To determine the cellular localization of SOD1,
we performed double-labeling ﬂuorescent confocal microscopy,
detecting both SOD1 and GFAP. Low SOD1 and GFAP expressionFig. 3. Cellular localization of SOD1-G93A transgene in the lumbar spinal cord and motor
Tissue sections of lumbar spinal cord and motor cortex of the transgenic mice at onset st
labeling ﬂuorescent confocal microscopy. (A) GFAP and SOD1 expression was low in the lu
transgenic mice at the onset stage (e–h) and SOD1 expression co-localized with GFAP exp
Hoechst. Arrow: a SOD1-positive remanent neuron. (e0–h0) were enlargements of the dot
positive astrocytes did not proliferate or over-express SOD1 compared with non-transgen
positive. Bar = 100 lm.were detected in the lumbar spinal cord of the non-transgenic lit-
termates, with SOD1 mainly expressed in neurons and astrocytes
and GFAP expressed in astrocytes. However, their expression levels
were very high at disease onset in the transgenic mice (Fig. 3A),
which is consistent with the Western blot results shown in
Fig. 2. Moreover, except for SOD1-positive remanent neurons,
SOD1 expression co-localized nicely with GFAP-positive astrocytes
in the lumbar spinal cord of the transgenic mice at disease onset
(Fig. 3A). These results suggest that the SOD1-G93A transgene is
over-expressed in both the proliferating astrocytes and neurons
in the lumbar spinal cord of SOD1-G93A transgenic mice. In con-cortex of symptomatic SOD1-G93A transgenic mice and non-transgenic littermates.
age and their littermates at the same age were subjected to GFAP and SOD1 double-
mbar spinal cord of non-transgenic littermates (a–d), but markedly increased in the
ression nicely (e0–h0). GFAP was used to locate astrocytes. Nuclei were labeled with
ted areas in (e–h), respectively. (a–h) Bar = 200 lm. (e0–h0) Bar = 100 lm. (B) GFAP-
ic littermates in the motor cortex (arrows indicate astrocytes). Neurons were SOD1-
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mice did not proliferate and expressed low SOD1 level (Fig. 3B).
Using immunohistochemistry, we observed low basal SOD1
expression in both cytoplasm and nucleus of neurons in the lumbar
spinal cord of non-transgenic littermates. However, in SOD1-G93A
transgenic mice, much higher intensity of SOD1 expression was
found at any disease stages including 60 days, onset and end
stages. Notably, many dark-brown SOD1-positive motor neurons
were noticed in the lumbar anterior horn of SOD1-G93A transgenic
mice at 60 days of age. Besides, some astrocyte-like SOD1-positive
cells were also observed, which was in accordance with the results
of confocal microscopy (Supplementary Fig. 1).
3.4. Different HO-1 reactivity in the CNS and HO-1 cellular localization
in the lumbar spinal cord of SOD1-G93A transgenic mice
HO-1 expression levels were relatively low in the CNS tissues of
non-transgenic littermates and did not show signiﬁcant change
over the time course. Therefore, littermates at 110–130 days were
used as non-transgenic control in the Western blot analysis. HO-1Fig. 4. Time course of HO-1 expression in CNS tissues of SOD1-G93A transgenic mic
symptomatic stage, disease onset or end stage and their non-transgenic littermates at the
lumbar spinal cord and motor cortex of the transgenic mice at different stages and thei
expression in (B and C), respectively. *P < 0.05 compared with non-transgenic littermateexpression level was low in SOD1-G93A transgenic mice at 60 days
of age, similar to their littermates. However, its level in the spinal
cord of the transgenic mice, particularly in the lumbar spinal cord,
increased signiﬁcantly at disease onset and end stages. In contrast,
HO-1 levels in motor cortex of the transgenic mice were not chan-
ged signiﬁcantly with the disease progression (Fig. 4).
To determine the cellular localization of HO-1, we performed
double-labeled ﬂuorescent confocal microscopy (Supplementary
Fig. 2). HO-1 expression was barely detectable in the cytoplasm
of neurons in the lumbar spinal cord of non-transgenic littermates,
but readily detected in the lumbar spinal cord of the transgenic
mice at disease onset. Some of the remanent neurons were
strongly HO-1 positive, showing clear cytoplasmic staining, consis-
tent with the known cellular location of HO-1. Most of the HO-1-
positive cells were astrocytes, based on the co-localization of HO-
1 and GFAP. We further performed HO-1 immunohistochemistry,
and achieved the same results as confocal microscopy did. HO-1
was low-expressed mainly in the cytoplasm of neurons in the lum-
bar spinal cord of non-transgenic littermates. The intensity of HO-1
immunoreactivity increased in SOD1-G93A transgenic mice.e. (A) HO-1 levels in various CNS tissues of SOD1-G93A transgenic mice at pre-
same ages were measured by Western blot. (B and C) HO-1 expression levels in the
r non-transgenic littermates at 110–130 days of age. (D and E) Histograms of HO-1
s. Pre-sympt, representative of pre-symptomatic stage.
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peared in the lumbar anterior horn nearby motor neurons at
60 days of age and increased and hypertrophied with the disease
progression, which was in accordance with the results found in
confocal microscopic examination. These proliferated HO-1 posi-
tive astrocyte-like cells were not detected in the lumbar dorsal
horn. Meanwhile, some individual HO-1 strongly positive neurons
were also observed as in the confocal microscopic photographs
(Supplementary Fig. 3).4. Discussion
To the best of our knowledge, this is the ﬁrst time that differen-
tial expression of human SOD1 transgene has been shown in the
CNS tissues of SOD1-G93A transgenic mice. The expression of
SOD1-G93A transgene was signiﬁcantly higher in the spinal cord
than in the brainstem, cerebellum, hippocampus and cortex. More-
over, in the lumbar spinal cord, the expression of this transgene in-
creased as the disease progressed. However, similar difference was
found on wild type human SOD1 transgene expression between
lumbar spinal cord and motor cortex of human SOD1 transgenic
mice. Therefore, the relatively high expression of mutant human
SOD1 is not the only reason contributed to the vulnerability of
spinal cord in SOD1-G93A mice. Our RT-PCR results further
showed that the SOD1-G93A transgene mRNA level in lumbar
spinal cord was much lower than that in motor cortex of SOD1-
G93A transgenic mice. Thus, we speculate that there may be a dis-
turbance of mutant SOD1 degradation in the lumbar spinal cord,
while the over-expressed wild type hSOD1 in the lumbar spinal
cord could be properly degraded and did not cause toxic injury
to motor neurons. We also showed that SOD1-G93A transgene
was mainly expressed in motor neurons forming aggregations at
presymptomatic stage (60 days of age), and with the disease pro-
gression, astrocytes proliferated and over-expressed SOD1-G93A
protein. SOD1-G93A expressing astrocytes are toxic to motor neu-
rons by releasing unidentiﬁed molecules in vitro [14] and enhance
microglial activation [15]. Therefore, SOD1-G93A expressing astro-
cytes could be accelerator of motor neuron death and disease pro-
gression and contribute to spinal cord vulnerability.
GLT-1, which is predominantly astroglial, is known to play a cru-
cial role in maintaining a normal extracellular glutamate level. Our
present study showed that tissue levels of GLT-1 differed among
different CNS tissues in non-transgenic littermate mice. Its level
in the spinal cord, particularly after adjustment by GFAP expres-
sion, was similar to those in medulla oblongata, pons, but much
lower than that in hippocampus and cortex. It has been widely
shown that astrocytes become reactive in ALS transgenic mice,
known as reactive gliosis. Increase of astrocyte number and hyper-
trophy of astrocyte processes are two hallmarks of reactive gliosis,
which would resulted in upregulation of its cytoskeleton known as
GFAP [16]. We further observed a progressively increased level of
GFAP protein, accompanied by decreased GLT-1 protein levels in
the lumbar spinal cord of SOD1-G93Amice, but no changes of GFAP
and GLT-1 were detected in the cortex of these animals. Several
studies have documented a loss of GLT-1 in ALS patients [17,18],
SOD1-G93A transgenic rat [10] and SOD1-G93A transgenic mice
[11]. Indeed, in vitro studies showed that the toxic effect of
SOD1-G93A could cause a speciﬁc post-translational down regula-
tion of GLT-1 by increasing the removal of the transporter from the
cell surface and targeting the internalized transporter for degrada-
tion [19]. In our study, spinal cord changes of GLT1 and GFAP appear
to follow SOD1-G93A transgene expression, since the expression le-
vel of neither GLT1 nor GFAP in the SOD1-G93A spinal cord at
60 days of age was different from that in the littermates, while
SOD1-G93A transgene signiﬁcantly over-expressed at that time.HO-1 is sensitive to oxidative stress and is up-regulated in re-
sponse to a wide variety of stimuli, including hypoxia, depletion
of reduced glutathione, nitric oxide and others [20–23]. Up regula-
tion of HO-1 may confer protection against oxidative insults both
in vitro [24,25] and in vivo [26,27]. HO-1 induction has been re-
ported in SOD1-G93A transgenic rats [28] and other neurodegener-
ative diseases, such as AD and PD [29,30]. In this study, HO-1 was
used as a marker of oxidative stress, although up-regulation of HO-
1 may also enhance cytoprotection. Its expression was signiﬁcantly
induced in the spinal cord in a time-dependent manner in SOD1-
G93A mice, reaching maximal levels at the end stage, whereas no
signiﬁcant HO-1 induction was observed in the other CNS tissues.
HO-1 immunoreactivity was increased in the lumbar anterior horn
of SOD1-G93A mice and characteristically co-localized with GFAP.
These results suggest that the reactive astrocytes in the spinal cord
are under signiﬁcant oxidative stress. However, HO1 induction in
the spinal cord was secondary to SOD1-G93A expression, as the
latter gene was already highly expressed at 60 days of age, when
no induction of HO-1 had yet occurred.
In conclusions, spinal cord vulnerability in human SOD1-G93A
transgenic mice is closely correlated with activated astrocytes
expressing high levels of SOD1-G93A transgene and HO-1 and
low level of GLT-1. ALS therapies aimed at these aspects will be
prospective.
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